Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02936479 · ClinicalTrials.gov registry record · Phase 2
C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT02936479: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT02936479 is a Phase 2 study that has completed, run by NYU Langone Health. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02936479, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A maximum of 5 patients will be enrolled.
Primary Outcome
number of patients that presented with severe and refractory Antibody Mediated Renal (AMR) following kidney transplant and survived beyond one year after study drug administration
Interventions
- DRUG C1-INH (Berinert)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-10-30 |
| Phase | Phase 2 |
What the finished NCT02936479 record still lists
NCT02936479 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which C1-INH (Berinert) is the first listed.
NCT02936479 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02936479 about?
NCT02936479 is a clinical study titled "C1-Inhibitor (INH) for Refractory Antibody Mediated Renal Allograft Rejection". This is an open-label, single arm trial in which patient who have ongoing antibody mediated rejection of a kidney transplant deemed refractory to maximal medical therapy are given the complement inhibitor C1-INH (Berinert) in an effort to protect the graft from ongoing antibody mediated injury. A ma...
What is the current status of trial NCT02936479?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2016-10. Estimated completion is 2018-10-30.
What interventions are being tested in trial NCT02936479?
The interventions under investigation include: C1-INH (Berinert) (DRUG).
Who is sponsoring clinical trial NCT02936479?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02936479's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia